SCHEMBL831384

SCHEMBL831384

Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)NS(=O)(=O)C3CC3)n(Cc3cc(C(=O)NC4CC4)ccc3F)c2cc1F

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP2C8 P10632 1/20 0.47
MAPK14 Q16539 5/20 0.37
SCN9A Q15858 5/20 0.37
SCN2B O60939 4/20 0.37
SCN1B Q07699 4/20 0.37
SCN5A Q14524 2/20 0.37
SCN1A P35498 2/20 0.37
MAPT P10636 2/20 0.35
POLB P06746 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
PARP1 P09874 1/20 0.33
AURKA O14965 1/20 0.33
TPX2 Q9ULW0 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL832003 0.92 CYP2C8 (0.48) CYP2C8SCN9ASCN2BSCN1BSCN5A
SCHEMBL831949 0.90 CYP2C8 (0.51) CYP2C8SCN9ASCN2BSCN1BSCN5A
SCHEMBL10257171 0.90 CYP2C8 (0.51) CYP2C8SCN9ASCN2BSCN1BSCN5A
SCHEMBL832291 0.89 CYP2C8 (0.46) CYP2C8SCN9ASCN2BSCN1BSCN5A
SCHEMBL831754 0.89 CYP2C8 (0.46) CYP2C8SCN9ASCN2BSCN1BSCN5A
SCHEMBL831380 0.88 CYP2C8 (0.54) CYP2C8SCN9ASCN2BSCN1BSCN5A
SCHEMBL831673 0.87 CYP2C8 (0.48) CYP2C8SCN9ASCN2BSCN1BSCN5A
SCHEMBL8860835 0.86 CYP2C8 (0.47) CYP2C8SCN9ASCN2BSCN1BSCN5A
SCHEMBL831310 0.86 CYP2C8 (0.52) CYP2C8SCN9ASCN2BSCN1BSCN5A
SCHEMBL13395366 0.85 CYP2C8 (0.33) CYP2C8MAPK14SCN9ASCN2BSCN1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 CYP2C8 847/4885MAPK14 3703/4885SCN9A 3807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.